Pre-launch · We're opening Reserve Meds to a limited first cohort. Join the waitlist ›
Home / Drugs / Rhapsido

Rhapsido, vemurafenib class

Adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamines ยท Dermatology / allergy (chronic spontaneous urticaria)

About Rhapsido

Adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamines. It is an Oral BTK inhibitor (tablet, twice daily) approved by the US FDA in 2025 and may be accessible to international patients through Named Patient Program or personal-import pathways.

How Reserve Meds coordinates Rhapsido

  1. Patient or treating physician submits a named-patient request.
  2. Clinical team verifies appropriateness of Rhapsido for the patient and destination country.
  3. Treating physician issues prescription and clinical justification.
  4. Country-specific NPP / personal-import documentation is prepared.
  5. Rhapsido is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
  6. Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).

Access by country

Reserve Meds publishes a detailed country deep-dive for Rhapsido in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Rhapsido in BahrainFull deep-dive on regulatory pathway, costs, timing Rhapsido in BangladeshFull deep-dive on regulatory pathway, costs, timing Rhapsido in EgyptFull deep-dive on regulatory pathway, costs, timing Rhapsido in IndiaFull deep-dive on regulatory pathway, costs, timing Rhapsido in LebanonFull deep-dive on regulatory pathway, costs, timing Rhapsido in Sri LankaFull deep-dive on regulatory pathway, costs, timing Rhapsido in TurkeyFull deep-dive on regulatory pathway, costs, timing Rhapsido in the UAEFull deep-dive on regulatory pathway, costs, timing

Start a request for Rhapsido

Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.

Join the Rhapsido waitlist

About Rhapsido

Dermatology / allergy (chronic spontaneous urticaria)
Manufacturer: Novartis
Modality: Oral BTK inhibitor (tablet, twice daily)
Generic: remibrutinib

Why Reserve Meds

DSCSA-compliant US sourcing. Physician-led. On-pathway in every destination. Patient-first intake with a named concierge.

Related

Access pathways
Country guidance
Articles & guides